Quantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method
Statistics in Medicine · 2024
DOI: 10.1002/sim.10285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Stuart G Baker. Beteiligte Einrichtung: Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasms, Overdiagnosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Cancer Prevention, National Cancer Institute.
Abstract (Originalsprache)
Multicancer detection (MCD) tests use blood specimens to detect preclinical cancers. A major concern is overdiagnosis, the detection of preclinical cancer on screening that would not have developed into symptomatic cancer in the absence of screening. Because overdiagnosis can lead to unnecessary and harmful treatments, its quantification is important. A key metric is the screen overdiagnosis fraction (SOF), the probability of overdiagnosis at screen detection. Estimating SOF is notoriously difficult because overdiagnosis is not observed. This estimation is more challenging with MCD tests because short‐term results are needed as the technology is rapidly changing. To estimate average SOF for a program of yearly MCD tests, I introduce a novel method that requires at least two yearly MCD tests given to persons having a wide range of ages and applies only to cancers for which there is no conventional screening. The method assumes an exponential distribution for the sojourn time in an operational screen‐detectable preclinical cancer (OPC) state, defined as once screen‐detectable (positive screen and work‐up), always screen‐detectable. Because this assumption appears in only one term in the SOF formula, the results are robust to violations of the assumption. An SOF plot graphs average SOF versus mean sojourn time. With lung cancer screening data and synthetic data, SOF plots distinguished small from moderate levels of SOF. With its unique set of assumptions, the SOF plot would complement other modeling approaches for estimating SOF once sufficient short‐term observational data on MCD tests become available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: Stuart G Baker
Förderung
- Division of Cancer Prevention, National Cancer Institute
Zitieren
APA
Baker, S. G. (2024). Quantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method. Statistics in Medicine. https://doi.org/10.1002/sim.10285
Vancouver
Baker SG. Quantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method. Statistics in Medicine. 2024. doi:10.1002/sim.10285
BibTeX
@article{Baker2024,
author = {Baker, Stuart G},
title = {Quantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method},
journal = {Statistics in Medicine},
year = {2024},
doi = {10.1002/sim.10285}
}
EUVIMED